Skip to main content
Fig. 8 | Journal of Translational Medicine

Fig. 8

From: Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model

Fig. 8

TIDE subtypes were closely related to ICB responses. A Comparisons of expression levels of immune checkpoint molecules among the TIDE subtypes of TCGA-BLCA. B Hypergeometric test revealed an association between TIDE subtypes of ICB.UC cohort and ICB responses (left), gray lines represent no significance; Stacked histogram showing the differences of ICB responses among the TIDE subtypes of ICB.UC cohort (right). R, response; NR, non-response. C Impacts of the TIDE subtypes and other predictive biomarkers on ICB efficacy, which were achieved by multivariate logistic regression analysis. D Transcription levels of the representative immune checkpoints including PD-1 (PDCD1), PD-L1 (CD274) and CTLA-4 from LY Dataset among the TIDE subtypes. E IF images of PD-1 (PDCD1), PD-L1 (CD274) and CTLA-4 using the collected real-world BC samples among the TIDE subtypes. Scale bar, 100 μm. F Analysis of the mean fluorescence intensity (AU) of PD-1 (PDCD1), PD-L1 (CD274) and CTLA-4 among the TIDE subtypes. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance

Back to article page